From: dph.immunizations@ct.gov <noreply@everbridge.net>

**Sent:** Monday, April 1, 2024 10:17 AM

Subject: CDC HAN #505: Increase in Invasive Serogroup Y Meningococcal Disease in the United States



Please click here to acknowledge receipt of this message

Dear CT Vaccine Program providers,

The Centers for Disease Control and Prevention (CDC) has issued a Health Alert (#505), Increase in Invasive Serogroup Y Meningococcal Disease in the United States, available <a href="https://example.com/here">here</a>.

The Connecticut Department of Public Health (CT DPH) has observed an increase in serogroup Y meningococcal disease similar to increases seen in other parts of the country as described in a new Centers for Disease Control and Prevention Health Alert Network (HAN) Health Advisory. Please see additional information attached about the increase in CT from CT DPH.

Thank you,

Sent on behalf of Lynn Sosa, MD State Epidemiologist Director of Infectious Diseases Connecticut Department of Public Health 410 Capitol Avenue, MS #11 TUB PO Box 340308 Hartford, CT 06134-0308



Manisha Juthani, MD Commissioner



Ned Lamont Governor Susan Bysiewicz Lt. Governor

To: Primary Care Staff, Infectious Disease, Emergency Medicine, Internal Medicine, Pediatrics, Family

Medicine, Laboratory Medicine, and Infection Control Personnel

From: Lynn Sosa, MD

**State Epidemiologist** 

Date: March 28, 2024

Subject: Meningococcal Disease Advisory

The Connecticut Department of Public Health (CT DPH) has observed an increase in serogroup Y meningococcal disease similar to increases seen in other parts of the country as described in this new Centers for Disease Control and Prevention Health Alert Network (HAN) Health Advisory.

- Seven case-patients with invasive meningococcal disease have been identified in Connecticut since October 2023. This exceeds the expected number of cases (yearly average 2013–2022: 3 cases). The increase is attributable to serogroup Y with genetic testing completed on isolates from 4 case-patients to date indicating sequence type (ST) 1466. This strain is *susceptible* to first-line antibiotics commonly used for treatment and close-contact prophylaxis.
- All CT case-patients were greater than 50 years of age (median age 66 years) and 3 (47%) were Black/African-American. All presented with bacteremia without the typical symptoms of meningitis.
- No common risk factor or epidemiologic link among cases has been identified indicating likely asymptomatic community transmission of this strain.
- Recommendations for providers:
  - o Maintain a heightened index of suspicion for invasive meningococcal disease in older age groups and be aware that patients with invasive meningococcal disease may present with bloodstream infection or other syndromes (e.g., bacteremic pneumonia, septic arthritis) without the symptoms typical of meningitis (e.g., headache, stiff neck).
  - Ensure that all people at increased risk for meningococcal disease are up to date on <u>MenACWY</u> <u>vaccine</u>. People at increased risk include those with HIV, asplenia, sickle cell disease, complement deficiency, and those taking complement inhibitor medications.
- Invasive (sterile body site) meningococcal disease is a Category 1 disease in Connectiut. All suspected and confirmed invasive meningococcal disease should be immediately reported to the CT DPH Epidemiology Program by phone (weekdays: (860) 509-7994, after hours: (860) 509-8000) and to the applicable local health department.



Phone: (860) 509-7994 • Fax: (860) 509-7910
Telecommunications Relay Service 7-1-1
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
www.ct.gov/dph
Affirmative Action/Equal Opportunity Employer

